EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Microbial Therapeutics for the Prevention and Treatment of Food Allergy

Susan V Lynch, Cathryn R Nagler, Rima Rachid

The Journal of Allergy and Clinical Immunology: In Practice · 2026

DOI: 10.1016/j.jaip.2026.02.024 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift The Journal of Allergy and Clinical Immunology: In Practice, 2026. Verfasst von Susan V Lynch und 2 weiteren Autor:innen. Beteiligte Einrichtung: Benioff Center for Microbiome Medicine, Department of Medicine, University of California, San Francisco, Calif. Hauptthemen laut MEDLINE: Food Hypersensitivity, Fecal Microbiota Transplantation, Gastrointestinal Microbiome, Probiotics.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Food allergy affects approximately 8% of children and 11% of adults in the United States. Available treatments, including oral immunotherapy and anti-IgE, are not known to lead to remission. There is now increasing evidence implicating the gut microbiome as a key regulator of allergic inflammation. Distinct microbial and metabolomic alterations characterize food-allergic individuals, and gnotobiotic mouse models show that fecal microbiota from food-allergic donors transfer allergic sensitization, whereas microbiota from healthy donors protect from anaphylaxis through induction of tolerogenic Foxp3+RORγt+ regulatory T cells (Tregs). Goblet cell-derived resistin-like molecule beta induces food allergy through modulation of the gut microbiome and depletion of indole-producing species. These findings have inspired the development of 5 microbial therapeutic approaches: probiotics, rationally defined bacterial consortia, fecal microbiota transplantation, metabolite-based approaches, and biologics targeting dysbiosis-associated pathways. Early-phase clinical studies support feasibility, yet long-term safety, durability, and reproducibility remain uncertain. Major challenges include interindividual variability, ecological complexity, and regulatory standardization. Microbiome-directed therapeutics hold promise to transform food allergy management from temporary desensitization toward remission and durable immune tolerance. The application of systems biology approaches integrating metabolomics, transcriptomics, and immune phenotyping will be essential to unravel the complex host-microbial interactions that underlie the efficacy of these approaches.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Food HypersensitivityFecal Microbiota TransplantationGastrointestinal MicrobiomeProbioticsHumansAnimalsImmune ToleranceT-Lymphocytes, RegulatoryDysbiosisDesensitization, Immunologic

Stichwörter der Autor:innen

Fecal microbiota transplantationFood allergyGut microbiomeMetabolitesMicrobial therapeuticsProbioticsRegulatory T cells

Autor:innen und Institutionen

  • Benioff Center for Microbiome Medicine, Department of Medicine, University of California, San Francisco, Calif.
  • Biological Sciences Division and Pritzker School of Molecular Engineering, The University of Chicago, Chicago, Ill.
  • Division of Immunology, Department of Pediatrics, Boston Children's Hospital, Harvard Medical School, Boston, Mass. Electronic address: rima.rachid@childrens.harvard.edu.

Zitieren

APA

Lynch, S. V., Nagler, C. R., & Rachid, R. (2026). Microbial Therapeutics for the Prevention and Treatment of Food Allergy. The Journal of Allergy and Clinical Immunology: In Practice. https://doi.org/10.1016/j.jaip.2026.02.024

Vancouver

Lynch SV, Nagler CR, Rachid R. Microbial Therapeutics for the Prevention and Treatment of Food Allergy. The Journal of Allergy and Clinical Immunology: In Practice. 2026. doi:10.1016/j.jaip.2026.02.024

BibTeX
@article{Lynch2026,
  author = {Lynch, Susan V and Nagler, Cathryn R and Rachid, Rima},
  title = {Microbial Therapeutics for the Prevention and Treatment of Food Allergy},
  journal = {The Journal of Allergy and Clinical Immunology: In Practice},
  year = {2026},
  doi = {10.1016/j.jaip.2026.02.024}
}
Kostenlos starten →